CAS NO: | 161903-10-2 |
包装: | 50mg, 100mg, 250mg |
规格: | ≥98% |
Doranidazole, formerly known as PR-000350; PR-350; RP-343; PR-69, is radiosensitizer and potentially for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. PR-350 was an effective hypoxic cell radiosensitizer for a human small cell lung cancer in vivo, in which necrotic change was dominant following irradiation. The magnitude of radiosensitization of tumors by doranidazole is dependent on the oxygenation status of the tumors and that doranidazole may be useful in increasing the response of hypoxic human pancreatic tumor to IORT. References: Yasui H, Asanuma T, Kino J, Yamamori T, Meike S, Nagane M, Kubota N, Kuwabara M, Inanami O. The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption. BMC Cancer. 2013 Mar 8;13:106. doi: 10.1186/1471-2407-13-106. PubMed PMID: 23496909; PubMed Central PMCID: PMC3599813.
纯度:≥98%
CAS:161903-10-2